Índice Bovespa

US Dollar vs BRL

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

HSP

Hospira (HSP)

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NYSE:HSP

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
22/04/2015	21:12	Dow Jones News	Meet Pharma's Newest Movers and Shakers, Driving M&A	NYSE:HSP
13/04/2015	04:30	PR Newswire (US)	Hope for Greater Access for Patients to Biosimilar Medicines	NYSE:HSP
10/04/2015	10:31	Edgar (US Regulatory)	Proxy Statement - Merger or Acquistion (definitive) (defm14a)	NYSE:HSP
07/04/2015	17:52	Dow Jones News	Hospira Gets Warning Letter on Quality Issues at Italy Plant	NYSE:HSP
07/04/2015	17:30	PR Newswire (US)	Hospira to Announce First-Quarter 2015 Results on April 28, 2015	NYSE:HSP
07/04/2015	11:50	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:HSP
01/04/2015	17:41	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:HSP
30/03/2015	12:33	PR Newswire (Canada)	INFLECTRA™ (Infliximab) de Hospira est désormais offert au Canada	NYSE:HSP
30/03/2015	12:30	PR Newswire (Canada)	Hospira's INFLECTRA™ (Infliximab) Now Available in Canada	NYSE:HSP
27/03/2015	10:00	PR Newswire (US)	Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalenc...	NYSE:HSP
23/03/2015	18:44	The Motley Fool	This Market Could Grow 6250% in 10 Years	NYSE:HSP
23/03/2015	08:02	The Motley Fool	3 Big Pharma Stocks Wall Street Is Wrong About	NYSE:HSP
20/03/2015	17:18	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NYSE:HSP
20/03/2015	17:02	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NYSE:HSP
06/03/2015	13:39	PR Newswire (US)	Hospira Statement on FDA Approval of the First Biosimilar in the United States	NYSE:HSP
27/02/2015	20:20	Edgar (US Regulatory)	Proxy Statement - Merger or Acquistion (preliminary) (prem14a)	NYSE:HSP
25/02/2015	20:15	Dow Jones News	Generic Copies of Remicade Go on Sale in Europe	NYSE:HSP
23/02/2015	13:06	GlobeNewswire Inc.	UPDATE - INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Hospira Inc. of Class Action Against the Board of the Co...	NYSE:HSP
19/02/2015	09:07	PR Newswire (US)	Inflectra™ (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease	NYSE:HSP
18/02/2015	17:34	Business Wire	HOSPIRA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout	NYSE:HSP
17/02/2015	22:30	Business Wire	HOSPIRA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of the Hospira, Inc. (HSP) Board of Directors in ...	NYSE:HSP
17/02/2015	12:40	GlobeNewswire Inc.	Investor Lawsuit Against Acquisition of Hospira, Inc. (HSP) Announced by Shareholders Foundation	NYSE:HSP
16/02/2015	07:55	PR Newswire (US)	Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra™ (infliximab) in major European markets	NYSE:HSP
13/02/2015	17:39	PR Newswire (US)	Lifshitz & Miller Law Firm Announces Investigation of E2open, Inc., Entropic Communications, Inc., Exelis, Inc., Hospira, Inc...	NYSE:HSP
12/02/2015	20:23	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NYSE:HSP
12/02/2015	19:39	Dow Jones News	Painkiller in Short Supply Following Hospira Recall -- Update	NYSE:HSP
12/02/2015	13:45	Edgar (US Regulatory)	Schedule 13g (sc 13g)	NYSE:HSP
12/02/2015	11:21	Dow Jones News	Hospira Profit Tops Expectations on Injectables Strength	NYSE:HSP
12/02/2015	11:03	Edgar (US Regulatory)	Annual Report (10-k)	NYSE:HSP
12/02/2015	10:30	PR Newswire (US)	Hospira Reports Fourth-Quarter and Full-Year 2014 Results	NYSE:HSP

Apresentando as notícias mais relevantes sobre:NYSE:HSP

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 Próxima >>

Índice Bovespa

Neogrid Participacoes ON

PÃO DE AÇUCAR ON

MAGAZINE LUIZA ON

CM Hospitalar ON

Agrogalaxy Participacoes ON

LOJAS MARISA ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições